Table 3.

Characteristics of HMAClax therapy

Median time from REL to HMAClax, months (range)	1.8 (0.3–42.9)
Planned administration of VEN 21/28 d, n	13/19
Combination partner of VEN	n
AZA/DAC, n	12/19#
AZA/DAC + DLI, n	11
Median number of cycles per patient	2 (1–19)
Total number of cycles,	90
Median duration of cycle	33 days (17–92)
Number of days with VEN	21 days (5–92)
Non-fatal tumor lysis syndrome	3 patients

REL relapse, HMA hypomethylating agent, HMAClax HMA + venetoclax, DLI donor lymphocyte infusion, VEN venetoclax